The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.
Saved in:
| Title: | The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. |
|---|---|
| Authors: | Subbiah, V.1 vsubbiah@mdanderson.org, Solit, D.B.2,3, Chan, T.A.4, Kurzrock, R.5 |
| Source: | Annals of Oncology. Sep2020, Vol. 31 Issue 9, p1115-1118. 4p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
